Menu
Not yet recruiting NCT07521241

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Phase I Interventional Chronic Liver Disease (CLD)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AD-230, AD-2301.
Who it may be relevant to
Registry conditions: Chronic Liver Disease (CLD). Basic parameters: 19 years — 64 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomized, Open-label, Two-treatment, Two-period, Two-sequence Crossover Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Overview

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Interventions

  • Drug AD-230, AD-2301
    Oral administration of AD-230 or AD-2301, according to randomized sequence.

Primary outcome measures

  • AUClast [Time frame: -24hours to 72hours]
  • Cmax [Time frame: -24hours to 72hours]

Eligibility criteria

Inclusion criteria

  • \- Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
  • Subjects aged 19 years or older and under 65 years at the screening visit

Exclusion criteria

  • Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
  • Other exclusions applied

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Open label
Primary purpose
Treatment

Study locations

South Korea · 1 center
  • Kyungpook National university hospital — Seoul

Identifiers

NCT: NCT07521241 · AD-230BE

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗